View ValuationRafarma Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Rafarma Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 31Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of UzbekistanRafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.お知らせ • Dec 17Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals IncVaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc.お知らせ • Dec 02Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of MalaysiaRafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.お知らせ • Oct 20R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group. R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020.お知らせ • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.お知らせ • Aug 06R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Rafarma Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:RAFA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20120000N/Aアナリストによる今後の成長予測収入対貯蓄率: RAFAの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RAFAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RAFAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RAFAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RAFAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RAFAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:43終値2026/05/22 00:00収益2012/03/31年間収益2012/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rafarma Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 31Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of UzbekistanRafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.
お知らせ • Dec 17Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals IncVaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc.
お知らせ • Dec 02Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of MalaysiaRafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.
お知らせ • Oct 20R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group. R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020.
お知らせ • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.
お知らせ • Aug 06R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements.